^
Association details:
| Biomarker: | HER-2 amplification |
|---|---|
| Cancer: | Gallbladder Cancer |
| Drug: | lapatinib (EGFR inhibitor, HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Genomic Landscape and Targeted Treatment of Gallbladder Cancer: Results of a First Ongoing Prospective Study
Published date:
12/14/2020
Excerpt:
...patients of unresectable and/or metastatic GBC of age ≥18 years were enrolled. Four patients with ERBB2 amplification received trastuzumab and/or lapatinib, showed partial response, and maintained response beyond 12 weeks. One patient had mixed response, whereas two patients progressed on trastuzumab and lapatinib.
DOI:
10.1055/s-0040-1721180
